SCHEMBL97628

SCHEMBL97628

[CH2]CC(C)(C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL39647 0.82
SCHEMBL2745680 0.78
SCHEMBL1222857 0.75
SCHEMBL29098627 0.72
SCHEMBL1379262 0.72
SCHEMBL9727039 0.72
SCHEMBL6698823 0.72
SCHEMBL125055 0.72
SCHEMBL19736 0.70
SCHEMBL997476 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2152 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118240543-A Gemini quaternary ammonium salt surfactant depressurization and injection increasing system and preparation method thereof 中国石油天然气集团有限公司 2024-06-25 CN claimed
CN-115109036-B Quinazoline compound, composition and application thereof 北京赛特明强医药科技有限公司 2024-06-11 CN claimed
US-20240180932-A1 SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS NESTLE SA (CH) 2024-06-06 US claimed
WO-2024118887-A1 N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA BLUEPRINT MEDICINES CORPORATION (US) 2024-06-06 WO claimed
EP-4376830-A1 USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF RENAL DISEASES IN NON-HUMAN MAMMALS Boehringer Ingelheim Vetmedica GmbH (DE) 2024-06-05 EP claimed
EP-4376819-A1 USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF HYPERTENSION IN NON-HUMAN MAMMALS Boehringer Ingelheim Vetmedica GmbH (DE) 2024-06-05 EP claimed
EP-4376829-A1 USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES Boehringer Ingelheim Vetmedica GmbH (DE) 2024-06-05 EP claimed
WO-2024108010-A1 METHODS AND COMPOSITIONS FOR CONTROL OF PAIN AND INFLAMMATION BAYER ANIMAL HEALTH GMBH (DE) 2024-05-23 WO claimed
CN-112969683-B Process for the preparation of O-substituted serine derivatives 中外制药株式会社 2024-05-14 CN claimed
EP-3750894-B1 UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2024-04-03 EP claimed
EP-0665221-A1 VITAMIN D DERIVATIVE AND PROCESS FOR PRODUCING THE SAME Chugai Seiyaku Kabushiki Kaisha (JP) 1995-08-02 EP claimed
EP-0657478-A2 An improved process for the preparation of water soluble polymer dispersion NALCO CHEMICAL COMPANY (US) 1995-06-14 EP claimed
EP-0344288-B1 METHOD OF INHIBITING THE ACTIVITY OF LEUKOCYTE DERIVED CYTOKINES HOECHST ROUSSEL PHARMA (US) 1995-02-15 EP claimed
EP-0637598-A2 Hydrophobic dispersants used in forming polymer dispersions NALCO CHEMICAL COMPANY (US) 1995-02-08 EP claimed
EP-0344288-A4 METHOD OF INHIBITING THE ACTIVITY OF LEUKOCYTE DERIVED CYTOKINES 1992-01-15 EP claimed
EP-0344288-A1 METHOD OF INHIBITING THE ACTIVITY OF LEUKOCYTE DERIVED CYTOKINES HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1989-12-06 EP claimed
WO-1989005145-A1 METHOD OF INHIBITING THE ACTIVITY OF LEUKOCYTE DERIVED CYTOKINES HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1989-06-15 WO claimed
EP-0030109-B1 PROCESS FOR PRODUCING ISOPRENE KURARAY CO., LTD. (JP) 1983-10-05 EP claimed
US-4381416-A Process for producing isoprene KURARAY CO., LTD. (JP) 1983-04-26 US claimed
EP-0030109-A1 Process for producing isoprene KURARAY CO., LTD. (JP) 1981-06-10 EP claimed